---
$id: https://graph.org.ai/products/commodity/51112011
$type: Product
source: UNSPSC
code: "51112011"
title: "Vatalanib"
class: "51112000"
classTitle: "Tyrosine kinase inhibitors"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Vatalanib

**UNSPSC Code**: 51112011
**Class**: [Tyrosine kinase inhibitors](Tyrosine kinase inhibitors.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a tyrosine kinase inhibitor with the molecular formula C20H15ClN4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5DX9U76296, chemically known as 1-phthalazinamine, n-(4-chlorophenyl)-4-(4-pyridinylmethyl)- but generally known as vatalanib, which bears US NIH Compound Identifier 151194. European Medicines Agency schedules Vatalanib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26999. The term VATALANIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). Most nations schedule vatalanib under HS 29333999 and SITC 51574. As of Q4 2014, VATALANIB remains the US FDA Preferred Term for this commodity. Vatalanib bears US NLM identifiers UMLS ID C0912586 and NCI Concept Code C1868. SMILES: CLC1CCC(NC2NNC(C3C2CCCC3)CC2CCNCC2)CC1.

